Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$233.31
+5.0%
$199.79
$96.09
$238.56
$11.43B0.61604,713 shs781,973 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.57
+4.0%
$22.92
$13.15
$27.72
$11.80B1.697.49 million shs8.12 million shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$23.75
+2.6%
$27.55
$9.39
$83.60
$11.45B1.65101,736 shs94,145 shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$21.47
-0.1%
$22.39
$2.96
$28.41
$3.11B1.192.90 million shs1.33 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+5.02%-0.51%+12.97%+44.50%+111.89%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+3.89%+3.64%+8.99%+2.58%+82.53%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
+2.59%+0.17%-18.44%-1.90%+2,374,999,900.00%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-0.14%+9.26%+2.34%+27.80%+562.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$233.31
+5.0%
$199.79
$96.09
$238.56
$11.43B0.61604,713 shs781,973 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.57
+4.0%
$22.92
$13.15
$27.72
$11.80B1.697.49 million shs8.12 million shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$23.75
+2.6%
$27.55
$9.39
$83.60
$11.45B1.65101,736 shs94,145 shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$21.47
-0.1%
$22.39
$2.96
$28.41
$3.11B1.192.90 million shs1.33 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+5.02%-0.51%+12.97%+44.50%+111.89%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+3.89%+3.64%+8.99%+2.58%+82.53%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
+2.59%+0.17%-18.44%-1.90%+2,374,999,900.00%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-0.14%+9.26%+2.34%+27.80%+562.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.267.69% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2014.78% Upside
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
1.00
SellN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.64
Moderate Buy$32.2750.32% Upside

Current Analyst Ratings Breakdown

Latest TNGX, AXSM, ELAN, and RGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
DowngradeSell (D-)Sell (E+)
5/15/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Boost Price TargetOutperform$20.00 ➝ $30.00
5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
DowngradeOverweightNeutral$16.00 ➝ $24.00
5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Set Price Target$55.00
5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
DowngradeBuyHold$18.00 ➝ $27.00
5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Boost Price TargetOutperform$28.00 ➝ $55.00
5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Boost Price TargetOutperform$19.00 ➝ $33.00
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/11/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
UpgradeSell (E+)Sell (D-)
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$28.00 ➝ $30.00
(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M18.80N/AN/A$1.75 per share133.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.60$2.41 per share10.18$13.18 per share1.86
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/A$0.01 per shareN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$62.38M49.79N/AN/A$2.57 per share8.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A50.18N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.302.54-4.95%7.42%3.66%8/6/2026 (Estimated)
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-$3.58MN/AN/AN/AN/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)

Latest TNGX, AXSM, ELAN, and RGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.32-$0.32N/A-$0.32$0.58 millionN/A
5/8/2026Q1 2026
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/A-$0.0050N/A-$0.0050N/AN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
3/5/2026Q4 2025
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.31-$0.29+$0.02-$0.29$0.56 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/A
1.41
N/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
27.38
27.38

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.13%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
2.00%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
10494.49 million484.60 millionN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
90144.65 million135.25 millionOptionable

Recent News About These Companies

Stifel Remains Bullish on Tango Therapeutics (TNGX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$233.31 +11.15 (+5.02%)
Closing price 06/3/2026 03:58 PM Eastern
Extended Trading
$232.92 -0.39 (-0.17%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.57 +0.94 (+3.97%)
Closing price 06/3/2026 03:58 PM Eastern
Extended Trading
$24.51 -0.06 (-0.25%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Regencell Bioscience stock logo

Regencell Bioscience NASDAQ:RGC

$23.75 +0.60 (+2.59%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$23.42 -0.33 (-1.41%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$21.47 -0.03 (-0.14%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$21.40 -0.07 (-0.31%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.